# US 2013/0156774 A1 · Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156774 A1
- Document ID: US20130156774A1
- Status: Published application
- Kind: A1
- Application number: 13/805,030
- Filed: 2011-06-16
- Published: 2013-06-20
- Earliest claimed: 2010-06-18
- Assignees: The Brigham and Women's Hospital, Inc.
- Inventors: Vijay K. Kuchroo; Ana C. Anderson
- Web page: https://patentgrep.com/patent/US20130156774A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/31: multispecific
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.

## Claims

### Claim 1

A multispecific polypeptide agent comprising at least one binding site that specifically binds to a PD-1 molecule, and at least one binding site that specifically binds to a TIM-3 molecule.

### Claim 2 (depends on 1)

The polypeptide agent of claim 1, wherein the polypeptide agent is a bispecific polypeptide agent comprising a binding site that specifically binds to a PD-1 molecule, and a binding site that specifically binds to a TIM-3 molecule.

### Claim 3 (depends on 1)

The polypeptide agent of claim 1, wherein the multispecific polypeptide agent is a multispecific antibody or a multispecific antibody fragment thereof.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The polypeptide agent of claim 1, wherein the agent binds a PD-1 molecule having the sequence set forth in SEQ ID NO:1, or is an allelic or splice variant of SEQ ID NO:1.

### Claim 6 (depends on 1)

The polypeptide agent of claim 1, wherein the agent binds a TIM-3 molecule having the sequence set forth in SEQ ID NO:2, or is an allelic or splice variant of SEQ ID NO:2.

### Claim 7 (depends on 1)

The polypeptide agent of claim 1, wherein the binding site that specifically binds to the PD-1 molecule is directed against a PD-1 ligand interaction site.

### Claim 8 (depends on 1)

The polypeptide agent of claim 1, wherein the binding site that specifically binds to the TIM-3 molecule is directed against a TIM-3 ligand interaction site.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 7)

The polypeptide agent of claim 7, wherein specific binding to the PD-1 ligand interaction site modulates interaction of PD-1 with PD-L1, PD-L2, or PD-L1 and PD-L2.

### Claim 12 (depends on 7)

The polypeptide agent of claim 7, wherein the ligand interaction site of PD-1 comprises amino acid residues 41-136 of SEQ ID NO:1.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 8)

The polypeptide agent of claim 8, wherein specific binding to the TIM-3 ligand interaction site modulates interaction of TIM-3 with galectin-9, phosphatidylserine, or galectin-9 and phosphatidylserine.

### Claim 18 (depends on 8)

The polypeptide agent of claim 8, wherein the TIM-3 ligand interaction site comprises amino acid residues 24-131 of SEQ ID NO:2.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

A method of treating a subject having a chronic immune condition, the method comprising administering to a subject having a chronic immune condition an effective amount of a multispecific polypeptide agent comprising at least one binding site that specifically binds to a PD-1 molecule, and at least one binding site that specifically binds to a TIM-3 molecule.

### Claim 22

A method of activating an immune response in a subject having a chronic immune condition, the method comprising administering to a subject having a chronic immune condition an effective amount of a multispecific polypeptide agent comprising at least one binding site that specifically binds to a PD-1 molecule, and at least one binding site that specifically binds to a TIM-3 molecule.

### Claim 23 (depends on 21)

The method of claim 21, wherein the chronic immune condition is a persistent infection.

### Claim 24 (depends on 21)

The method of claim 21, wherein the chronic immune condition is a cancer or a tumor.

### Claim 25 (depends on 21)

The method of claim 21, wherein the chronic immune condition comprises a population of functionally exhausted T cells.

### Claim 26 (depends on 25)

The method of claim 25, wherein the population of functionally exhausted T cells comprises a CD8+ T cell population.

### Claim 27 (depends on 21)

The method of claim 21, wherein the multispecific polypeptide agent is a multispecific antibody or a multispecific antibody fragment thereof.

### Claim 28 (depends on 21)

The method of claim 21, wherein the binding site that specifically binds to the PD-1 molecule is directed against a PD-1 ligand interaction site.

### Claim 29 (depends on 21)

The method of claim 21, wherein the binding site that specifically binds to the TIM-3 molecule is directed against a TIM-3 ligand interaction site.
